Forget Rescheduling: Green Thumb's Cash Flow Is the Real Reason to Own It
Green Thumb (GTBIF), a U.S. cannabis operator, reported 2025 GAAP earnings of $114.2M, operating cash flow of $294.9M, and normalized EBITDA of $348.4M. The company has repurchased $203.4M in stock. Q2 2026 EBITDA was $84.3M, with operating cash flow down to $104.8M. Federal rescheduling could boost profitability and stock price.
How this was made

The 30-second read
Why it matters
The disclosed earnings and cash flow data provide fresh insight into the company's financial health, influencing valuation models.
Market read
New earnings data for a profitable cannabis MSO could shift investor sentiment in the sector.
What to watch
Regulatory uncertainty remains high; any delay in federal rescheduling could suppress valuation despite strong cash flow.
Background
Green Thumb (GTBIF) is an OTC‑listed multi‑state cannabis operator with a market cap of about $1.4 billion.
Ticker impact
The article reports Green Thumb's 2025 GAAP earnings, 2026 Q2 EBITDA, and cash flow figures, marking the first public disclosure of these financial results.
potential modest upside as investors value cash flow strength, tempered by pressure if cash flow weakness persists
First-time earnings disclosure for a micro‑cap OTC stock provides new data; cash flow remains robust overall, supporting a bullish view, while the decline may limit gains.
Market effects
Highlights profitability potential in the cannabis sector, may prompt re‑rating of other cash‑flow positive MSOs.
U.S. cannabis investors may adjust exposure to profitable operators.
Limited to niche cannabis market; no broad macro impact.
Counterpoint
Cash flow decline could signal emerging operational challenges, suggesting a short‑term pullback.
Key entities
- companyGreen Thumb
OTC‑listed cannabis operator reporting new financial results.



